ABT-869

• Background:

  ABT-869 (796967-16-3) ia a structurally novel, potent inhibitor of receptor tyrosine kinases inhibiting VEGFR and PDGFR and related kinases with IC50s= 3, 4, 4, 66, 3 and 14 nM for VEGFR1, VEGFR2, FLT3, PDGFRβ, CSF-1R and KIT respectively.1,2 Protects cells from necroptosis and rescues SIRS mice from TNF-α-induced shock and death.3 Exerts anti-obesity effects by promoting adipocyte browning.4 Inhibits angiogenesis.5

• Conjugation:

  Unconjugated

• Buffer:

  Off-white solid

• Storage Conditions:

  -20°C